Introduction: Preclinical data showed that intercalated administration of epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective …

Randomized clinical trials (RCTs) of concurrent epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) plus chemotherapy for unselected patients with advanced non …

Background Trials investigating the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in
combination with chemotherapy in unselected patients with advanced non-small-cell lung …

Both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR
TKIs) are widely applied for the treatment of non-small cell lung cancer (NSCLC), but the …

Background Considering cell cycle dependent cytotoxicity, intercalation of chemotherapy
and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) may be a …

Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid
their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer …

背景与目的 化疗与表皮生长因子受体酪氨酸激酶抑制剂 (epidermal growth factor receptor-
tyrosine kinase inhibitors, EGFR-TKIs) 联合疗法一直是许多研究的焦点 …

Soon after the discovery of activating mutations of epidermal growth factor receptor (EGFR)
and of their crucial role in determining sensitivity to tyrosine kinase inhibitors (TKIs), several …

Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in
patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of …

Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of …